BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37770905)

  • 1. LncRNA like NMRK2 mRNA functions as a key molecular scaffold to enhance mitochondrial respiration of NONO-TFE3 rearranged renal cell carcinoma in an NAD
    Chen Y; Lu Y; Yang L; Ma W; Dong Y; Zhou S; Liu N; Gan W; Li D
    J Exp Clin Cancer Res; 2023 Sep; 42(1):252. PubMed ID: 37770905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up-regulation of NMRK2 mediated by TFE3 fusions is the key for energy metabolism adaption of Xp11.2 translocation renal cell carcinoma.
    Chen Y; Yang L; Lu Y; Liu N; Ma W; Fan H; Hu Q; Han X; Gan W; Li D
    Cancer Lett; 2022 Jul; 538():215689. PubMed ID: 35447281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N
    Yang L; Chen Y; Liu N; Shi Q; Han X; Gan W; Li D
    J Hematol Oncol; 2021 Mar; 14(1):46. PubMed ID: 33741027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The suitability of NONO-TFE3 dual-fusion FISH assay as a diagnostic tool for NONO-TFE3 renal cell carcinoma.
    Liu N; Guo W; Shi Q; Zhuang W; Pu X; Chen S; Qu F; Xu L; Zhao X; Li X; Zhang G; Guo H; Gan W; Li D
    Sci Rep; 2020 Oct; 10(1):16361. PubMed ID: 33004995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].
    Zhao YN; Wang XT; Xia QY; Wang GP; Sun SY; Zhao LF; Zhou XJ; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):574-579. PubMed ID: 30107660
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma: A Comparative Study With Papillary and Clear Cell Renal Cell Carcinomas.
    Wei S; Krause HB; Geynisman DM; Elliott A; Kutikov A; Uzzo RG; Pei J; Barata P; Carneiro B; Heath E; Ryan C; Farrell A; Nabhan C; Ali-Fehmi R; Naqash AR; Argani P; McKay RR
    Mod Pathol; 2024 Feb; 37(2):100404. PubMed ID: 38104891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NONO-TFE3 Fusion Promotes Aerobic Glycolysis and Angiogenesis by Targeting HIF1A in NONO-TFE3 Translocation Renal Cell Carcinoma.
    Chen Y; Yang L; Liu N; Shi Q; Yin X; Han X; Gan W; Li D
    Curr Cancer Drug Targets; 2021; 21(8):713-723. PubMed ID: 33845743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CircMET promotes tumor proliferation by enhancing CDKN2A mRNA decay and upregulating SMAD3.
    Yang L; Chen Y; Liu N; Lu Y; Ma W; Yang Z; Gan W; Li D
    Mol Cancer; 2022 Jan; 21(1):23. PubMed ID: 35042525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The positive regulation loop between NRF1 and NONO-TFE3 fusion promotes phase separation and aggregation of NONO-TFE3 in NONO-TFE3 tRCC.
    Wang B; Gan W; Han X; Liu N; Ma T; Li D
    Int J Biol Macromol; 2021 Apr; 176():437-447. PubMed ID: 33592266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.
    Yu W; Wang Y; Rao Q; Jiang Y; Zhang W; Li Y
    Pathol Res Pract; 2019 Sep; 215(9):152521. PubMed ID: 31277953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement.
    Xia QY; Wang Z; Chen N; Gan HL; Teng XD; Shi SS; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
    Mod Pathol; 2017 Mar; 30(3):416-426. PubMed ID: 27934879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and Characterization of a
    Ishiguro M; Fukushige T; Iwasaki H
    Anticancer Res; 2023 Aug; 43(8):3463-3470. PubMed ID: 37500159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of SCD1 in TFE3-rRCC and its effect on proliferation and migration].
    Dong YH; Liuxu WT; Chen Y; Gan WD; Li DM
    Zhonghua Nan Ke Xue; 2023 Aug; 29(8):682-687. PubMed ID: 38619513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NONO::TFE3 fusion cutaneous epithelioid and spindle cell tumor: A case series.
    See SHC; Olivares S; Kulkarni M; Dhillon SK; Fumero-Velazquez MS; Hagstrom MNE; Gerami P
    J Cutan Pathol; 2023 Nov; 50(11):956-962. PubMed ID: 37606377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
    Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
    Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas.
    Mathur M; Samuels HH
    Oncogene; 2007 Jan; 26(2):277-83. PubMed ID: 16832349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma.
    Pei J; Cooper H; Flieder DB; Talarchek JN; Al-Saleem T; Uzzo RG; Dulaimi E; Patchefsky AS; Testa JR; Wei S
    Mod Pathol; 2019 May; 32(5):710-716. PubMed ID: 30622287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases.
    Hodge JC; Pearce KE; Wang X; Wiktor AE; Oliveira AM; Greipp PT
    Mod Pathol; 2014 Jan; 27(1):113-27. PubMed ID: 23828314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors.
    Skalsky YM; Ajuh PM; Parker C; Lamond AI; Goodwin G; Cooper CS
    Oncogene; 2001 Jan; 20(2):178-87. PubMed ID: 11313942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
    Baba M; Furuya M; Motoshima T; Lang M; Funasaki S; Ma W; Sun HW; Hasumi H; Huang Y; Kato I; Kadomatsu T; Satou Y; Morris N; Karim BO; Ileva L; Kalen JD; Wilan Krisna LA; Hasumi Y; Sugiyama A; Kurahashi R; Nishimoto K; Oyama M; Nagashima Y; Kuroda N; Araki K; Eto M; Yao M; Kamba T; Suda T; Oike Y; Schmidt LS; Linehan WM
    Mol Cancer Res; 2019 Aug; 17(8):1613-1626. PubMed ID: 31043488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.